BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35536994)

  • 1. Use of Cabozantinib to Treat MET -amplified Pediatric Colorectal Cancer.
    Fukui S; Umeda K; Kubota H; Iwai A; Akazawa R; Isobe K; Tanaka K; Kouzuki K; Kawabata N; Saida S; Kato I; Hiramatsu H; Itatani Y; Funakoshi T; Adachi S; Takita J
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):e423-e426. PubMed ID: 35536994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
    Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
    Sun Y; Sun L; An Y; Shen X
    Med Sci Monit; 2015 Aug; 21():2316-21. PubMed ID: 26255947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
    Wedekind MF; Ranalli M; Shah N
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
    Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
    Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 12. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to cabozantinib in renal cell carcinoma with cardiac metastases.
    Stellato M; Cursano MC; Citarella F; Pantano F; Russano M; Dell' Aquila E; Vincenzi B; Tonini G; Santini D
    Anticancer Drugs; 2020 Mar; 31(3):314-318. PubMed ID: 31929349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
    Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
    Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
    Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
    Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
    Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
    Rabinowits G; Lezcano C; Catalano PJ; McHugh P; Becker H; Reilly MM; Huang J; Tyagi A; Thakuria M; Bresler SC; Sholl LM; Shapiro GI; Haddad R; DeCaprio JA
    Oncologist; 2018 Jul; 23(7):814-821. PubMed ID: 29445030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating mutation in MET oncogene in familial colorectal cancer.
    Neklason DW; Done MW; Sargent NR; Schwartz AG; Anton-Culver H; Griffin CA; Ahnen DJ; Schildkraut JM; Tomlinson GE; Strong LC; Miller AR; Stopfer JE; Burt RW
    BMC Cancer; 2011 Oct; 11():424. PubMed ID: 21970370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.